Dong-Hyeon Kim

12PUBLICATIONS
31CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMedical infection agents (incl. prions)Food safety, traceability, certification and authenticity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Apr 15, 2026
Impact of Immunogenicity on Clinical Outcomes in Patients With Moderate-to-Severe Inflammatory Bowel Disease Receiving Subcutaneous Infliximab: A Post Hoc Analysis of the LIBERTY Trials.

|Mar 30, 2026
Symptom Response Dynamics for Personalised Therapy with Subcutaneous Infliximab in Crohn's Disease: Insights from the Randomised, Placebo-Controlled, Phase 3 LIBERTY-CD Trial.

Stefan Schreiber, Bruce E Sands, Silvio Danese

|Mar 25, 2026
Pharmacokinetics and efficacy of subcutaneous infliximab 120 mg every 2 weeks: a post hoc comparison with intravenous dosing in a phase 1 study in patients with inflammatory bowel disease.

Stefan Schreiber, Byong Duk Ye, Hyunseong Yu

|Mar 18, 2026
Recovery of response and long-term outcomes following loss of response and dose escalation of subcutaneous infliximab: a post hoc analysis of the LIBERTY-CD & LIBERTY-UC trials.

Marla C Dubinsky, Stefan Schreiber, Andres J Yarur

|Jan 19, 2026
Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn's Disease: A Systematic Literature Review and Network Meta-Analysis.

Stefan Schreiber, Silvio Danese, Jean-Frédéric Colombel

|Apr 02, 2023
Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial.

Geert D'Haens, Walter Reinisch, Stefan Schreiber

Pageof 2

Frequent Collaborators

5 joint publications

Young Nam Lee

5 joint publications

Kun-Ho Seo

4 joint publications

Hyunsook Kim

4 joint publications

Stefan Schreiber